Compass Pathways PLC
NASDAQ:CMPS
Intrinsic Value
Compass Pathways Plc functions as an investment holding company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CMPS.
Compass Pathways PLC's market capitalization is 519.6m USD.
CMPS stock price is 8.09 USD.
CMPS.
CMPS. Open DCF Valuation
CMPS. Open Relative Valuation
CMPS has upside potential of 420% compared to the average analyst price target.
Open Wall St Estimates
CMPS has negative Free Cash Flow for the last twelve months.
CMPS has negative Operating Income for the last twelve months.
CMPS has negative Net Income for the last twelve months.
CMPS's ROE (Return on Equity) for the past 12 months is negative and is equal to -58%.
CMPS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -258%.
CMPS's Altman Z-Score is very high and is equal to 3.36.
CMPS's D/E (Debt to Equity) is very low and is equal to 0.13.
CMPS has negative three-year average ROE (Return on Equity): -40%. The company is not efficient at transforming stockholders' equity into net income.
CMPS has negative three-year average ROIC (Return on Invested Capital): -361%. The company is not efficient at using invested capital to generate operating income.
CMPS's short-term assets (261m USD) exceed its short-term liabilties (20m USD).
CMPS's long-term assets (276m USD) exceed its long-term liabilties (50m USD).
CMPS has negative Net Debt. This means that the company has more cash and short-term investments (220m USD) than debt (29m USD).
CMPS doesn't generate enough operating income (-127m USD) to safely cover interest payments on its debt (1m USD).
Fundamental Analysis
Compass Pathways PLC
Balance Sheet Decomposition
Compass Pathways PLC
| Current Assets | 261.3m |
| Cash & Short-Term Investments | 220.2m |
| Receivables | 28.9m |
| Other Current Assets | 12.2m |
| Non-Current Assets | 14.7m |
| Long-Term Investments | 469k |
| PP&E | 4.7m |
| Other Non-Current Assets | 9.5m |
| Current Liabilities | 19.6m |
| Accounts Payable | 5.9m |
| Accrued Liabilities | 12.7m |
| Other Current Liabilities | 1m |
| Non-Current Liabilities | 30.6m |
| Long-Term Debt | 28.8m |
| Other Non-Current Liabilities | 1.9m |
Earnings Waterfall
Compass Pathways PLC
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-127.1m
USD
|
|
Operating Income
|
-127.1m
USD
|
|
Other Expenses
|
8.7m
USD
|
|
Net Income
|
-118.5m
USD
|
Free Cash Flow Analysis
Compass Pathways PLC
CMPS Profitability Score
Profitability Due Diligence
Compass Pathways PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Compass Pathways PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
CMPS Solvency Score
Solvency Due Diligence
Compass Pathways PLC's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Compass Pathways PLC's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CMPS Price Targets Summary
Compass Pathways PLC
According to Wall Street analysts, the average 1-year price target for
CMPS
is 42.08 USD
with a low forecast of 22.22 USD and a high forecast of 126 USD.
Ownership
CMPS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CMPS Price
Compass Pathways PLC
| Average Annual Return | -21.1% |
| Standard Deviation of Annual Returns | 62.62% |
| Max Drawdown | -91% |
| Market Capitalization | 525.4m USD |
| Shares Outstanding | 64 230 000 |
| Percentage of Shares Shorted | 5.5% |
Company Profile
Compass Pathways PLC
Country
Industry
Market Cap
Dividend Yield
Description
Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.
You don't have any saved screeners yet
